Oligodendrocyte lineage transcription factor 2 (OLIG2) mRNA (OLIG2 mRNA)

Oligodendrocyte lineage transcription factor 2 (OLIG2) mRNA encodes a basic helix-loop-helix transcription factor essential for the specification and differentiation of oligodendrocytes and motor neurons (UniProt: P50213). In malignant gliomas, particularly glioblastoma, OLIG2 is highly expressed and acts as a key driver of tumor initiation, progression, and resistance to standard therapies like radiation (PubMed: 21841786). Because the OLIG2 protein is traditionally considered undruggable by small molecules, targeting its mRNA via antisense oligonucleotides (ASOs) or RNA interference (RNAi) has emerged as a promising therapeutic strategy to downregulate protein expression (PubMed: 25611381). These nucleic acid-based approaches aim to inhibit the pro-proliferative and anti-apoptotic signaling pathways maintained by OLIG2 in cancer cells. Beyond oncology, OLIG2 dysregulation is implicated in neurodevelopmental disorders such as Down syndrome and certain types of leukemia. However, therapeutic development faces significant hurdles, including the need for efficient delivery across the blood-brain barrier and the risk of impairing normal myelination processes in the central nervous system.

Other names

BHLHB1BHLHE19PRKCBP2RACK17Oligodendrocyte transcription factor 2 mRNA

Antisense oligonucleotides (ASOs) bind to the OLIG2 mRNA to trigger RNase H-mediated degradation or block translation, while siRNAs utilize the RNA-induced silencing complex (RISC) to cleave the mRNA, both resulting in reduced levels of the OLIG2 transcription factor.